Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price target on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating on the stock in a research report on Thursday, May 2nd.

Check Out Our Latest Stock Report on NERV

Minerva Neurosciences Stock Down 0.9 %

Shares of Minerva Neurosciences stock opened at $3.15 on Thursday. Minerva Neurosciences has a twelve month low of $2.26 and a twelve month high of $13.49. The stock has a market cap of $22.02 million, a price-to-earnings ratio of -0.70 and a beta of 0.13. The company’s fifty day moving average is $2.74 and its 200 day moving average is $4.67.

Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. As a group, equities analysts anticipate that Minerva Neurosciences will post -1.89 earnings per share for the current fiscal year.

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders.

Featured Stories

• Five stocks we like better than Minerva Neurosciences
• 3 Natural Gas Stocks That Offer Great Dividend Yields
• Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
• How to Invest in Biotech Stocks
• General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
• Why Invest in 5G? How to Invest in 5G Stocks  
• Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs

Receive News & Ratings for Minerva Neurosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Minerva Neurosciences and related companies with MarketBeat.com’s FREE daily email newsletter.

You might be interested in: